A Dispenzieri

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc The clinical spectrum of Castleman's disease
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:997-1002. 2012
  2. pmc How I treat POEMS syndrome
    Angela Dispenzieri
    Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:5650-8. 2012
  3. pmc Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:517-23. 2012
  4. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
  5. doi request reprint POEMS syndrome: update on diagnosis, risk-stratification, and management
    Angela Dispenzieri
    Am J Hematol 87:804-14. 2012
  6. doi request reprint What do I need to know about immunoglobulin light chain (AL) amyloidosis?
    Angela Dispenzieri
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood Rev 26:137-54. 2012
  7. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
  8. ncbi request reprint Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3400-7. 2004
  9. ncbi request reprint Treatment of POEMS syndrome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 5:249-57. 2004
  10. ncbi request reprint A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005

Research Grants

  1. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2009
  2. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
  3. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2006
  4. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2007
  5. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2010

Collaborators

Detail Information

Publications167 found, 100 shown here

  1. pmc The clinical spectrum of Castleman's disease
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:997-1002. 2012
    ..We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study...
  2. pmc How I treat POEMS syndrome
    Angela Dispenzieri
    Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:5650-8. 2012
    ..More universal recognition of and more scientific inquiry into the underpinnings of the disease will provide direction toward the best treatment strategies in the future...
  3. pmc Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:517-23. 2012
    ..To determine whether the free light chain (FLC) assay provides prognostic information relevant to the general population...
  4. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
    ..We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896...
  5. doi request reprint POEMS syndrome: update on diagnosis, risk-stratification, and management
    Angela Dispenzieri
    Am J Hematol 87:804-14. 2012
    ..POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome...
  6. doi request reprint What do I need to know about immunoglobulin light chain (AL) amyloidosis?
    Angela Dispenzieri
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood Rev 26:137-54. 2012
    ..In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction...
  7. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  8. ncbi request reprint Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3400-7. 2004
    ..Of the 14 evaluable patients, all have had neurologic improvement or stabilization. Other features have improved substantially. PBSCT for POEMS syndrome is effective therapy but may also be associated with significant morbidity...
  9. ncbi request reprint Treatment of POEMS syndrome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 5:249-57. 2004
    ..Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome...
  10. ncbi request reprint A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005
    ..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
  11. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  12. doi request reprint POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management
    Angela Dispenzieri
    Laboratory Medicine and Pathology, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 86:591-601. 2011
    ..POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome...
  13. ncbi request reprint Treatment options for POEMS syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 6:945-53. 2005
    ..Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome...
  14. ncbi request reprint Multiple myeloma: clinical features and indications for therapy
    Angela Dispenzieri
    Mayo Clinic, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:553-68. 2005
    ..These distinctions affect important management decisions. Other related disorders include primary systemic amyloidosis, POEMS syndrome, and acquired Fanconi syndrome...
  15. ncbi request reprint Neurological aspects of multiple myeloma and related disorders
    Angela Dispenzieri
    Mayo Clinic, Medicine, Rochester, Minnesota MN 55905, USA
    Best Pract Res Clin Haematol 18:673-88. 2005
    ..The authors will review the neurologic complications of MM, monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia (WM), POEMS syndrome, amyloidosis, and cryoglobulinemia...
  16. ncbi request reprint POEMS syndrome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, United States
    Blood Rev 21:285-99. 2007
    ..The role of anti-VEGF therapies, immune modulatory drugs, and proteasome inhibitors has not yet been defined, but drugs with known high rates of treatment related neuropathy should not be considered as first line therapy...
  17. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  18. pmc Appraisal of immunoglobulin free light chain as a marker of response
    Angela Dispenzieri
    Departments of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 111:4908-15. 2008
    ..Although baseline values of FLC are prognostic in newly diagnosed myeloma patients, serial measurements do not appear to have added value in patients who have M-proteins measurable by electrophoresis...
  19. doi request reprint International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    A Dispenzieri
    Department of Hematology Laboratory Medicine Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:215-24. 2009
    ..This paper provides consensus guidelines for the use of this important assay, in the diagnosis and management of clonal PCD...
  20. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  21. ncbi request reprint Complications of myeloma therapy
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 21:1247-73, xi. 2007
    ..The author provides perspective about the risks for the most active and commonly used single-agent and combination myeloma therapies...
  22. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  23. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  24. ncbi request reprint A phase II trial of imatinib in patients with refractory/relapsed myeloma
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 47:39-42. 2006
    ..Patients ended treatment due to progressive disease (18 patients), death (3) and other (2). The data suggest that imatinib is not an active agent in patients with relapsed or refractory multiple myeloma...
  25. pmc A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  26. pmc Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
    A Dispenzieri
    Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1406-11. 2010
    ..In high-risk patients, upfront bortezomib results in response rates that are comparable to those reported for unselected cohorts, but single agent bortezomib is not sufficient as primary therapy...
  27. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  28. doi request reprint Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 14:6-11. 2008
    ..Whenever possible, patients should be treated on clinical trials...
  29. ncbi request reprint Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Amyloid 10:257-61. 2003
    ..Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide...
  30. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  31. ncbi request reprint POEMS syndrome: definitions and long-term outcome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2496-506. 2003
    ..Additional features of the syndrome often develop, but the complications of classic multiple myeloma rarely develop...
  32. ncbi request reprint Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
    Angela Dispenzieri
    Division of Haematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 361:1787-9. 2003
    ..024 microg/L, less than 0.01 microg/L, and 0.084 microg/L, and for cTnI were 0.1 microg/L, 0.05 microg/L, and 0.24 microg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI...
  33. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  34. ncbi request reprint Treatment of Castleman's disease
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 6:255-66. 2005
    ..Patients with CD are at increased risk for developing frank malignant lymphoma...
  35. ncbi request reprint Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
    A Dispenzieri
    Division of Hematology and Internal Medicine, and Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:3350-6. 2001
    ..This article addresses the extent to which eligibility to undergo HSCT is a favorable prognostic feature and explores prognostic factors within the subset of eligible patients...
  36. doi request reprint Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
    S K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:1013-9. 2008
    ..6 months for Dex and were not reached for Thal-Dex and Len-Dex groups, P=0.2. For patients undergoing early ASCT for myeloma, the nature of initial treatment utilized has no long-term impact on the outcome of ASCT...
  37. ncbi request reprint Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:2035-42. 2007
    ..We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures...
  38. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
    ..The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma...
  39. ncbi request reprint Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
    S V Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 68:269-75. 2001
    ..It is also prognostic for poor survival and PFS following SCT for myeloma. We recommend that all three methods of estimating BMPC% be routinely performed and that the highest value be used for prognostic purposes...
  40. doi request reprint Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
    D Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 74:913-8. 2010
    ..Amyloidosis may present with autonomic neuropathy (AN) that renders peritransplant care problematic. The purpose of this study was to determine the outcome of patients with AN during and after ASCT...
  41. ncbi request reprint Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:235-9. 2004
    ..007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma...
  42. ncbi request reprint Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 98:579-85. 2001
    ..In conclusion, ALC is correlated with clinical outcome and requires further study. (Blood. 2001;98:579-585)..
  43. doi request reprint SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
    M A Gertz
    Division of Hematology, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:956-61. 2011
    ..The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors...
  44. ncbi request reprint High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:161-7. 2004
    ..65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT...
  45. pmc A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Leukemia 27:220-5. 2013
    ..The addition of Thal to standard ZLD produces anti-tumor responses whereas ZLD alone does not. Thal/ZLD also prolongs TTP from AMM to MM. This study provides the rationale for further studies in patients with AMM to delay chemotherapy...
  46. doi request reprint Impact of early relapse after auto-SCT for multiple myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:413-20. 2008
    ..Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches...
  47. ncbi request reprint Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation
    W J Hogan
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Bone Marrow Transplant 28:305-9. 2001
    ..The patient progressed from being wheelchair-bound to independent ambulation. An aggressive approach should be considered in patients with POEMS syndrome in whom standard therapeutic measures fail...
  48. ncbi request reprint Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center
    A Dispenzieri
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 48:1302-7. 2013
    ..This difference in survival is most notable among those patients who achieve CR, suggesting very different plasma cell biology between the two diseases. ..
  49. ncbi request reprint High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
    A Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Heart 100:383-8. 2014
    ..To define whether the high sensitivity cardiac troponin T (hs-cTnT) assay in patients with immunoglobulin light chain amyloidosis (AL) improves risk prediction...
  50. doi request reprint Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 48:557-61. 2013
    ..Patients with serum troponin T >0.06 ng/mL or NT-proBNP >5000 pg/mL (not on dialysis) should not be considered candidates for SCT because of early mortality...
  51. ncbi request reprint Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:624-7. 2004
    ..Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma...
  52. ncbi request reprint Thalidomide for previously untreated indolent or smoldering multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 15:1274-6. 2001
    ..Additional randomized trials are needed to determine if thalidomide will delay progression to active multiple myeloma...
  53. ncbi request reprint Thalidomide as initial therapy for early-stage myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 17:775-9. 2003
    ..Thalidomide has significant activity in early-stage myeloma and has the potential to delay progression to symptomatic disease. This approach must be further tested in randomized trials...
  54. ncbi request reprint Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:1025-31. 2004
    ..Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy...
  55. ncbi request reprint Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:485-90. 2004
    ..18. No significant differences were observed in the progression-free and overall survival at 1 year post transplant. Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma...
  56. ncbi request reprint Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
    David Dingli
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:384-8. 2006
    ..The impact of cyclophosphamide on CR rates and TTP was evaluated...
  57. pmc Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 28:1122-8. 2014
    ..Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably. ..
  58. pmc Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
    S V Rajkumar
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:1738-44. 2013
    ..001. There was a trend to shorter TTP with deletion 17p (median TTP, 24 months). Overall survival from diagnosis of SMM was significantly inferior with t(4;14) compared with t(11;14), median 105 versus 147 months, respectively, P=0.036. ..
  59. doi request reprint Second auto-SCT for treatment of relapsed multiple myeloma
    W I Gonsalves
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55906, USA
    Bone Marrow Transplant 48:568-73. 2013
    ..Hence, auto-SCT2 is an effective and feasible therapeutic option for MM patients relapsing after other treatments, especially in patients who had a TTP of at least 12 months after their auto-SCT1...
  60. ncbi request reprint Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma
    F K Buadi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1017-22. 2006
    ..The outcome may not be different from that of younger patients in terms of TRM and EFS...
  61. ncbi request reprint Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma
    R Howe
    Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Bone Marrow Transplant 32:317-24. 2003
    ....
  62. doi request reprint Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:689-96. 2011
    ....
  63. ncbi request reprint Prognostic value of bone marrow angiogenesis in multiple myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 6:3111-6. 2000
    ..Angiogenesis is correlated with the plasma cell labeling index but not the bone marrow plasma cell percentage. A simple visual grading of angiogenesis is an efficient alternative to microvessel density estimation...
  64. pmc Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 43:619-25. 2009
    ..Our data suggested that CY damaged the microenvironment and slowed engraftment. By lengthening the period between the completion of apheresis and stem cell reinfusion, the microenvironment may recover and result in faster engraftment...
  65. ncbi request reprint Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
    I M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 32:587-92. 2003
    ..008), but platelet transfusion requirements did not differ (P=0.95). We concluded that thalidomide does not substantially affect peripheral cell mobilization or engraftment...
  66. ncbi request reprint Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
    S R Hayman
    Departments of Hematology and Internal Medicine and of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:2266-8. 2001
    ..2%) of those had translocation (11;14)(q13;q32) for an overall prevalence of the abnormality of 55%. IgH translocations are common in AL, especially the t(11;14)(q13;q32)...
  67. pmc Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
    M R Litzow
    Division of Hematology, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:490-7. 2010
    ..04). Topotecan can safely be dose escalated to 4.5 mg/m(2)/d in combination with CY, carboplatin and AHSCT. This trial is registered at ClinicalTrials.gov as NCT00652691...
  68. doi request reprint Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 46:970-5. 2011
    ..Improved supportive care and refined patient selection have improved the safety margin of patients undergoing auto-SCT; short-term mortality showed a more than 40% decrease after 2005...
  69. ncbi request reprint Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 39:605-11. 2007
    ..Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation...
  70. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
    ..To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS...
  71. ncbi request reprint Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
    M A Elliott
    Hematology Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1003-8. 2006
    ..Nevertheless, consistent with reported experience of others, overall outcomes remain less than optimal and unpredictable...
  72. pmc Impact of additional cytoreduction following autologous SCT in multiple myeloma
    Sk Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:259-64. 2008
    ....
  73. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  74. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  75. ncbi request reprint Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)
    M A Gertz
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 40:989-93. 2007
    ..Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL...
  76. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  77. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...
  78. pmc Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
    K Detweiler Short
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:906-8. 2011
    ..Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002)...
  79. doi request reprint Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  80. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  81. ncbi request reprint Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
    Hans P Sviggum
    Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Dermatol 142:1298-302. 2006
    ....
  82. ncbi request reprint High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:381-5. 2001
    ..The mean post-transplant hospital stay for those with GI tract bleeding was 37 days compared with 14.5 days for those who did not have GI tract bleeding (P = 0.0047)...
  83. doi request reprint Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...
  84. ncbi request reprint The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:1085-92. 2004
    ..Multivariate analysis demonstrated A-ALC as an independent prognostic indicator for OS and TTP. These results indicate that an infused dose of autograft lymphocytes significantly impacts clinical outcome post-APHSCT in MM...
  85. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  86. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  87. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  88. pmc Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
    Apollina Goel
    Molecular Medicine Program, College of Medicine, Mayo Clinic, Guggenheim 1833, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:4063-70. 2006
    ..PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the efficacy of skeletal-targeted radiotherapy in multiple myeloma...
  89. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  90. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  91. pmc Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  92. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  93. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  94. ncbi request reprint Recurrent membranoproliferative glomerulonephritis after kidney transplantation
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Kidney Int 77:721-8. 2010
    ..Our study shows the risk of MPGN recurrence and progression depends on identifiable pretransplant characteristics, has variable clinical impact, and can result in graft failure...
  95. ncbi request reprint In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  96. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  97. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:343-60. 2006
    ..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy...
  98. ncbi request reprint Primary cardiac amyloidosis with 20-year survival
    Michael E Fealey
    Mayo Work Study Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cardiovasc Pathol 15:331-5. 2006
    ..The natural history of primary amyloidosis is poor, and for patients with symptomatic cardiac involvement, survival is generally less than 6 months. Even among treated patients with amyloid heart disease, survival beyond 5 years is rare...
  99. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  100. ncbi request reprint Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:158-64. 2006
    ..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM...
  101. ncbi request reprint Natural history and therapy of 66 patients with mixed cryoglobulinemia
    Alan H Bryce
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 81:511-8. 2006
    ..Treatment is generally directed at the underlying condition. Not all patients require treatment, and many can be followed and treated symptomatically...

Research Grants5

  1. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2009
    ..MV-NIS, given by vein, should kill myeloma cells. Using simple scans, we should be able to track where MV-NIS goes in the body. ..
  2. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
    ..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
  3. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2006
    ..MV-NIS, given by vein, should kill myeloma cells. Using simple scans, we should be able to track where MV-NIS goes in the body. ..
  4. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2007
    ..MV-NIS, given by vein, should kill myeloma cells. Using simple scans, we should be able to track where MV-NIS goes in the body. ..
  5. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2010
    ..MV-NIS, given by vein, should kill myeloma cells. Using simple scans, we should be able to track where MV-NIS goes in the body. ..